| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC2244 |
| Trial ID | NCT04160195 |
| Disease | B-Cell Chronic Lymphocytic Leukemia | B-Cell Lymphoma | Non-Hodgkin's Lymphoma |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD20 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Terminated |
| Title | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma |
| Year | 2020 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 200008|20-C-0008 |
| Cohort 1 | |||||||||
|
|||||||||